Other substances

Dactolisib

A dual PI3K/mTOR inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Dactolisib is an orally bioavailable experimental imidazoquinoline drug. It inhibits phosphatidylinositol 3 kinase and the mammalian target of rapamycin. It suppresses cell growth and chemo-/radiotherapy resistance and thus displays a potential to be used as an antineoplastic agent (NCIt).

Dactolisib on DrugBank
Dactolisib on PubChem
Dactolisib on Wikipedia


Synonyms

NVP-BEZ235; BEZ-235

 

Structure image - Dactolisib

CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

Supporting references

Link Tested on Impact factor Notes Publication date
Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19
Preprint 		VERO E6 cell cultures Apr/09/2020
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
Small molecule In vitro Mechanism 		Vero E6 cells; Calu-3 cells; HEK293-ACE2 cells; HeLa-ACE2 cells; A549-ACE2 cells; human-induced pluripotent stem-cell-derived cardiomyocyte; SARS-CoV-2 isolate USA-WA1/2020 8.11

Inhibited SARS-CoV-2 infection in Vero E6 cells. It displayed some cytotoxicity, however.

 Mar/17/2021

AI-suggested references

Link Publication date
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19
May/20/2021
Export (.csv)